Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
No statistically significant intergroup differences were detected for PTH, 25(OH)D, 24-hour urinary calcium, or 24-hour urinary phosphate.
Source: Biochemical profile and comparative analysis between TIO and primary osteoporosis patients. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Assays for study participants were conducted at the laboratory of Kingmed Diagnostics in Boao, Hainan, using the manufacturer’s (DiaSorin) CLIA kit on a LIAISON XL automated analyzer.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Unveiling the biochemical signature of tumor-induced osteomalacia: implications for distinguishing it from primary osteoporosis
Study design awaiting verification · Frontiers in Endocrinology · 2026
Original publication title
Unveiling the biochemical signature of tumor-induced osteomalacia: implications for distinguishing it from primary osteoporosis
Copyright © 2026 Chai, Wang, Li, Wei, Chen, Wang, He, Liu and Feng.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by FGF23-secreting tumors, resulting in renal phosphate wasting and hypophosphatemic osteomalacia. Low bone mineral density (BMD) in TIO frequently leads to misdiagnosis as the more prevalent primary osteoporosis (POP) and subsequent diagnostic delay. This study characterizes the distinct biochemical profile of TIO and proposes a stepwise diagnostic approach to differentiate it from POP for timely clinical identification and appropriate management.
Source: PurposeAbstract: What methods does the paper describe?
We conducted a retrospective comparative analysis of 11 TIO patients and 12 POP patients managed at our institution over a 14-year period. Detailed clinical data were collected and compared between groups, including history, physical examination findings, laboratory results, imaging studies, and pathological outcomes.
Source: MethodsAbstract: Results
Comparative analysis revealed that, compared with POP patients, TIO patients had significantly lower serum calcium (2.19 ± 0.1 vs.2.3 ± 0.1 mmol/L, p < 0.05), serum phosphorus [0.46 (0.42, 0.6) vs. 1.15 (1.13, 1.23), p < 0.001], and the tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR) (0.41 ± 0.2 vs.1.05 ± 0.15 mmol/L, p < 0.001). In contrast, ALP was significantly higher in the TIO cohort [317 (177.5, 344) vs. 79.5 (67.75, 86.75) U/L, p < 0.001].
No significant intergroup differences were observed in PTH levels or BMD.
Source: ResultsAbstract: Conclusions
We recommend serum phosphate, alkaline phosphatase, and TmP/GFR tests for symptomatic patients (e.g., bone pain, muscle weakness). Confirmed hypophosphatemia warrants FGF23 testing after excluding other causes of elevation. Subsequent bone X-ray and BMD guides the need for molecular imaging. The diagnostic gold standard comprises: (1) histopathological confirmation of the causative tumor, (2) rapid postoperative serum phosphate normalization, and (3) significant clinical improvement.
Source: ConclusionsAuthors’ abstract
Purpose
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by FGF23-secreting tumors, resulting in renal phosphate wasting and hypophosphatemic osteomalacia. Low bone mineral density (BMD) in TIO frequently leads to misdiagnosis as the more prevalent primary osteoporosis (POP) and subsequent diagnostic delay. This study characterizes the distinct biochemical profile of TIO and proposes a stepwise diagnostic approach to differentiate it from POP for timely clinical identification and appropriate management.
Methods
We conducted a retrospective comparative analysis of 11 TIO patients and 12 POP patients managed at our institution over a 14-year period. Detailed clinical data were collected and compared between groups, including history, physical examination findings, laboratory results, imaging studies, and pathological outcomes.
Results
Comparative analysis revealed that, compared with POP patients, TIO patients had significantly lower serum calcium (2.19 ± 0.1 vs.2.3 ± 0.1 mmol/L, p < 0.05), serum phosphorus [0.46 (0.42, 0.6) vs. 1.15 (1.13, 1.23), p < 0.001], and the tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR) (0.41 ± 0.2 vs.1.05 ± 0.15 mmol/L, p < 0.001). In contrast, ALP was significantly higher in the TIO cohort [317 (177.5, 344) vs. 79.5 (67.75, 86.75) U/L, p < 0.001].
No significant intergroup differences were observed in PTH levels or BMD.
Conclusions
We recommend serum phosphate, alkaline phosphatase, and TmP/GFR tests for symptomatic patients (e.g., bone pain, muscle weakness). Confirmed hypophosphatemia warrants FGF23 testing after excluding other causes of elevation. Subsequent bone X-ray and BMD guides the need for molecular imaging. The diagnostic gold standard comprises: (1) histopathological confirmation of the causative tumor, (2) rapid postoperative serum phosphate normalization, and (3) significant clinical improvement.
Publication and source details
Original title: Unveiling the biochemical signature of tumor-induced osteomalacia: implications for distinguishing it from primary osteoporosis
Yun Chai; Xin Wang; Sen Li; Zhiwang Wei; Qiusong Chen; Baoping Wang; Qing He; Ming Liu; Wenli Feng
Frontiers in Endocrinology · 2026
* Correspondence: Wenli Feng, fengwenli1@126.com†These authors have contributed equally to this work and share first authorship
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T22:03:03.735622+00:00
DOI: 10.3389/fendo.2026.1899331 · PMC13447073